Publication | Open Access

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

Checkmate 025UrologyPrior TherapyGenitourinary CancerMedicineCancer ManagementRandomized Phase 3Immune Checkpoint InhibitorMolecular OncologyCancer TreatmentOncologyRadiation OncologyCancer Research